Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignJonathan W. Riess, Paul K. Paik, Joel M. Reid et al.|Clinical Lung Cancer|2020Cited by 65
Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.Jonathan W. Riess, David R. Gandara, Susan Groshen et al.|Journal of Clinical Oncology|2019Cited by 18
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W. Riess, Primo N. Lara, Karen L. Reckamp et al.|Clinical Lung Cancer|2021Cited by 18
Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.Jonathan W. Riess, David R. Gandara, Mark Krailo et al.|Journal of Clinical Oncology|2022Cited by 12